Description: Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; and GT1708F, for the treatment of leukaemia and basal-cell carcinoma. The company was founded in 2009 and is headquartered in Suzhou, China.
Home Page: www.kintor.com.cn
No. 20 Songbei Road
Suzhou,
215123
China
Phone:
86 51 2626 39909
Officers
| Name | Title |
|---|---|
| Dr. Youzhi Tong | Founder, CEO & Exec. Chairman |
| Ms. Yan Lu | CFO, Joint Company Sec. & Exec. Director |
| Dr. Qun Lu | Chief Technology Officer |
| Mr. Ma Liandong | VP and Head of R&D Institute |
| Mr. Wai Chiu Wong FCS | Joint Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 15.5763 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.1453 |
| Price-to-Sales TTM: | 17.8566 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 328 |